Intratumoral Cancer Therapies Market Poised to Explode at a 49.10% CAGR, Reaching USD 4,193 Million by 2034

DelveInsight's, "Intratumoral Cancer Therapies Treatment Market Insight, Epidemiology and Market Forecast - 2034" report provides comprehensive insights about the Intratumoral Cancer Therapies market size, historical and forecasted epidemiology, current and emerging treatment landscape, and market opportunity across the 7MM (the United States; EU4 - Germany, France, Italy, and Spain; the United Kingdom; and Japan).

Download DelveInsight's comprehensive Intratumoral Cancer Therapies Market Report to explore emerging therapies, key players, and future treatment landscapes @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Intratumoral Cancer Therapies Market Report
• The Intratumoral Cancer Therapies market in the 7MM was valued at approximately USD 115 million in 2025 and is projected to grow at a CAGR of 49.10%, reaching USD 4,193 million by 2034.
• Among the selected indications for intratumoral therapies, non-melanoma accounted for the highest number of cases across the 7MM and is anticipated to increase at ~2.0% annually over the coming decade.
• Currently, only IMLYGIC (talimogene laherparepvec) is approved by the US FDA for melanoma treatment and garners more than 90% of the total intratumoral therapies market.
• In March 2024, ImmVira announced that the US FDA granted Fast Track designation for the oncolytic virus product MVR-T3011 IT for recurrent head and neck squamous cell cancer.
• In November 2023, Genelux announced that the US FDA granted Fast Track designation for Olvi-Vec (olvimulogene nanivacirepvec) for platinum resistant/refractory ovarian cancer.
• Among the emerging Intratumoral Cancer Therapies, OncoSec Medical's TAVO (tavokinogene telseplasmid), a plasmid-based Interleukin-12 therapy, is expected to generate the highest revenue.
• The leading Intratumoral Cancer Therapies Companies include Nanobiotix, Replimune, Sirnaomics, OncoSec Medical, Daiichi Sankyo, Amgen, Merck & Co (Viralytics), Moderna Therapeutics, Idera Pharmaceuticals, Philogen, Lokon Pharma, Hookipa Biotech, Vyriad, Intensity Therapeutics, and others.

Access DelveInsight's in-depth Intratumoral Cancer Therapies Market Analysis for a closer look at promising breakthroughs @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Intratumoral Cancer Therapies Market Report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM market size from 2020 to 2034. The report also covers current treatment market practices/algorithms and unmet needs to curate the best opportunities and assess the market's potential.

Intratumoral Cancer Therapies Overview
Cancer is a broad term for diseases caused by abnormal cells quickly dividing and spreading to other tissues and organs, and it is one of the world's major causes of death. Intratumoral therapy is a promising treatment option for several cancer types, using sophisticated antibodies or biologics injected directly into cancer tumors instead of intravenously. These therapies aim to deliver immunostimulatory products directly into a tumor lesion to prime and/or boost an antitumor immune response, generating a systemic immune response upon local immune stimulation. The objective of such a therapeutic strategy is to use the tumor as its own vaccine, generating a polyclonal adaptive immune response mediated by T and/or B cells against pre-existing tumor-specific or tumor-associated antigens.
Intratumoral Cancer Therapies Emerging Drugs Profile

HENSIFY (NBTXR3): Nanobiotix
HENSIFY is a first-in-class product introducing a new, physical mechanism of action, designed to physically destroy tumors and activate the immune system for local control and systemic disease treatment when combined with radiation therapy. It is an aqueous suspension of crystalline hafnium oxide nanoparticles injected directly into a tumor before a patient's first standard radiotherapy treatment, amplifying the localized tumor-killing effect of radiation. In February 2020, Nanobiotix received FDA Fast Track Designation for NBTXR3 activated by radiation therapy, with or without cetuximab, in locally advanced head and neck squamous cell cancer. Currently, the drug is in the Phase III stage of development for locally advanced head and neck squamous cell carcinoma.

STP705 (cotsiranib): Sirnaomics
STP705 is a dual-targeted siRNA therapeutic that uses polypeptide nanoparticle-enhanced delivery to knock down TGF-β1 and COX-2 gene expression directly. It has received Orphan Drug Designation for cholangiocarcinoma and primary sclerosing cholangitis. Currently, the drug is in late-stage clinical development for Squamous Cell Carcinoma in situ, has completed Phase II for Basal Cell Carcinoma, and is in Phase I for fat remodeling.

Explore groundbreaking therapies and clinical trials in the Intratumoral Cancer Therapies Market. Access DelveInsight's detailed report now! @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Intratumoral Cancer Therapies Market Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for Intratumoral Cancer Therapies, along with market size and share estimates by therapy.
• It assesses the different therapeutic candidates segmented into Phase III, Phase II, and Phase I stages of development.
• Intratumoral Cancer Therapies Companies are involved in developing targeted therapeutics spanning immune-potentiating cytokines, TLR and STING agonists, T-cell checkpoint inhibitors, suppressive cytokine inhibitors or traps, oncolytic viruses, and plasmid DNA.
• Intratumoral Cancer Therapies Drugs under development are assessed based on stage of development, route of administration, mechanism of action, and molecule type.
• Detailed analysis of collaborations, acquisitions and mergers, licensing, and patent details for future advancement of the Intratumoral Cancer Therapies Market.

Intratumoral Cancer Therapies Companies

Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix, and others.

Intratumoral Cancer Therapies Market Report provides the therapeutic assessment of the pipeline and marketed drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intratumoral
• Intralesional

Intratumoral Cancer Therapies Products have been categorized under various Molecule types such as
• Oncolytic virus
• siRNA (small interfering RNA)
• Nanoparticle
• TLR-9 receptor agonist
• Multi-kinase inhibitor
• Oncolytic peptide

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Intratumoral Cancer Therapies Market Report
• Coverage- 7MM (US, EU4, UK, Japan)
• Study Period- 2020-2034 (Forecast Period: 2023-2034)
• Intratumoral Cancer Therapies Companies- Nanobiotix, Replimune, Sirnaomics, OncoSec Medical, Daiichi Sankyo, Amgen, Merck & Co (Viralytics), Moderna Therapeutics, Idera Pharmaceuticals, Philogen, and others.
• Intratumoral Cancer Therapies- IMLYGIC (talimogene laherparepvec), DELYTACT (G47Δ), HENSIFY (NBTXR3), STP705 (cotsiranib), Vidutolimod + nivolumab, LTX-315, AIV001, TAVO, and others.
• Intratumoral Cancer Therapies Market CAGR (2025-2034)- 49.10%
• Intratumoral Cancer Therapies Therapeutic Assessment by Clinical Stages- Marketed, Phase III, Phase II, Phase I/II, Phase I

Find out in DelveInsight's exclusive Intratumoral Cancer Therapies Market Report-access it now! @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Introduction
2. Executive Summary
3. Intratumoral Cancer Therapies: Overview
4. Epidemiology and Patient Burden Assessment
5. Intratumoral Cancer Therapies Current Treatment Practices
6. Intratumoral Cancer Therapies Marketed Drugs
7. IMLYGIC (Talimogene laherparepvec): Amgen
8. DELYTACT (G47Δ): Daiichi Sankyo
9. Intratumoral Cancer Therapies Emerging Drugs
10. HENSIFY (NBTXR3): Nanobiotix
11. STP705 (cotsiranib): Sirnaomics
12. Intratumoral Cancer Therapies Pipeline Development Activities
13. Intratumoral Cancer Therapies Market Outlook and Drugs Uptake
14. Intratumoral Cancer Therapies Market Access and Reimbursement
15. Latest KOL Views on Intratumoral Cancer Therapies
16. Intratumoral Cancer Therapies Qualitative Analysis (SWOT and Conjoint Analysis)
17. Intratumoral Cancer Therapies Market Size and Forecast (2020-2034)
18. Intratumoral Cancer Therapies Key Companies
19. Intratumoral Cancer Therapies Market Drivers and Barriers
20. Appendix
21. About Us

Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.